Trial reportHaematologica2019
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pooled it
- A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).Cancer chemotherapy and pharmacology · 2022Trial
- Activity and toxicity of intramuscular 1000 iu/mBritish journal of haematology · 2022Trial
- Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach.European journal of drug metabolism and pharmacokinetics · 2022Trial
- Trial
- Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.Cancer chemotherapy and pharmacology · 2021Trial
- Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.Leukemia · 2026Review
- Metabolites associated with type 2 diabetes and Alzheimer's disease trigger differential intracellular signaling responses in mouse primary neurons.Brain research · 2025Article
- Pharmacokinetics of Pegaspargase with a Limited Sampling Strategy for Asparaginase Activity Monitoring in Children with Acute Lymphoblastic Leukemia.Pharmaceutics · 2025Article
- Exploring Escherichia coli EGY Type II L-Asparaginase Variant of Unique Glutaminase Activity: Cloning, Expression, Biochemical Characterization, and Molecular Docking Analysis.Current microbiology · 2025Article
- The Role of Candidate Polymorphisms in Drug Transporter Genes on High-Dose Methotrexate in the Consolidation Phase of the AIEOP-BFM ALL 2009 Protocol.Clinical and translational science · 2025Article
- The Current and Potential Role of Pediatric Clinical Pharmacologists in Italy: A Review with Evidence Synthesis and Literature Analysis.Current medicinal chemistry · 2025Review
- Outcome of the Modified St. Jude Total XV Protocol in Turkish Children with Newly Diagnosed Acute Lymphoblastic Leukemia: A Single-Center Retrospective AnalysisTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Differential responses of primary neuron-secreted MCP-1 and IL-9 to type 2 diabetes and Alzheimer's disease-associated metabolites.Scientific reports · 2024Article
- Acute Lymphoblastic Leukemia with Central Nervous System Involvement-Challenges in Management.Indian journal of pediatrics · 2024Review
- Differential responses of primary neuron-secreted MCP-1 and IL-9 to type 2 diabetes and Alzheimer's disease-associated metabolites.bioRxiv : the preprint server for biology · 2023Article
- Serum Amino Acid Profiling in Children with Autistic Spectrum Disorder: Insights from a Single-Center Study in Southern Romania.Healthcare (Basel, Switzerland) · 2023Article
- Antifungal Drug-Drug Interactions with Commonly Used Pharmaceutics in European Pediatric Patients with Acute Lymphoblastic Leukemia.Journal of clinical medicine · 2023Review
- Article
- Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?British journal of haematology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 15 institutions in 4 countries.
Carmelo RizzariPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy c.rizzari@asst-monza.it.
Claudia Lanvers-KaminskyDepartment of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.
Maria Grazia ValsecchiMedical Statistics Unit, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy.
Andrea BalleriniDepartment of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Cristina MatteoDepartment of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Joachim GerssInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
Gudrun WuerthweinDepartment of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.
Daniela SilvestriMedical Statistics Unit, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy.
Antonella ColombiniPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
Valentino ConterPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
Andrea BiondiPediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.
Martin SchrappeDepartment of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Anja MoerickeDepartment of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Martin ZimmermannDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Arend von StackelbergPediatric Hematology and Oncology, Charité, Berlin, Germany.
Christin LinderkampPediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Michael C FrühwaldChildren's Hospital, Augsburg, Germany.
Sabine LegienPediatrics 5 (Oncology, Hematology, Immunology); Stuttgart Cancer Center; Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
Andishe AttarbaschiDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
Bettina ReismüllerDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.
David KasperDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Petr SmisekCzech Paediatric Haematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
Jan StaryCzech Paediatric Haematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
Luciana VintiDepartment of Pediatric Hemato-Oncology, Ospedale Bambino Gesù, Rome, Italy.
Elena BarisoneDepartment of Pediatric Hemato-Oncology, Regina Margherita Children's Hospital, Turin, Italy.
Rosanna ParasoleDepartment of Pediatric Hematology-Oncology, Ospedale Pausillipon, Naples, Italy.
Concetta MicalizziDepartment of Pediatric Hematology-Oncology, IRCCS I.G. Gaslini, Genova, Italy.
Massimo ZucchettiDepartment of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Joachim BoosDepartment of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.
University of Milano-Bicocca · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity Hospital Münster · DEMedizinische Hochschule Hannover · DESt Anna Children's Hospital · ATBambino Gesù Children's Hospital · ITCharité - Universitätsmedizin Berlin · DECharles University · CZIstituto Giannina Gaslini · ITKlinikum Stuttgart · DEMedical University of Vienna · ATOspedale Regina Margherita · ITUniversity Hospital Augsburg · DEUniversity Hospital in Motol · CZUniversity of Münster · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asparagine levels in cerebrospinal fluid and serum asparaginase activity were monitored in children with acute lymphoblastic leukemia treated with pegylated-asparaginase. The drug was given intravenously at a dose of 2,500 IU/m
Indexed as
AdolescentAsparaginaseAsparagineAustriaChildChild, PreschoolCzech RepublicDrug MonitoringFemaleGermanyHumansInfantItalyMalePolyethylene GlycolsPrecursor Cell Lymphoblastic Leukemia-LymphomaAsparaginaseAsparaginepegaspargasePolyethylene Glycols
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.